

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/00, 51/04		A1	(11) International Publication Number: WO 97/06831
			(43) International Publication Date: 27 February 1997 (27.02.97)
(21) International Application Number: PCT/US96/13045		ASTON, Karl, W. [US/US]; 19040 Sunflower Ridge Lane, Pacific, MO 63069 (US).	
(22) International Filing Date: 16 August 1996 (16.08.96)		(74) Agents: ROTH, Michael, J. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	
(30) Priority Data: 60/002,422 17 August 1995 (17.08.95) US		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 60/002,422 (CON) Filed on 17 August 1995 (17.08.95)		Published With international search report.	
(71) Applicant (for all designated States except US): MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): NEUMANN, William, L. [US/US]; 844 Reindeer Drive, Ballwin, MO 63021 (US). RILEY, Dennis, P. [US/US]; 800 Chancellor Heights Drive, Ballwin, MO 63011 (US). WEISS, Randy, H. [US/US]; 3074 Woodbridge Estates Drive, St. Louis, MO 63129 (US). HENKE, Susan, L. [US/US]; 123 Parsons Avenue, Webster Groves, MO 63119 (US). LENNON, Patrick, J. [US/US]; 7540 Wydown Boulevard #3W, Clayton, MO 63105 (US).			

(54) Title: METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS

(57) Abstract

The present invention is directed to complexes represented by formula (I), wherein R, R', R₁, R'₁, R₂, R'₂, R₃, R'₃, R₄, R'₄, R₅, R'₅, R₆, R'₆, R₇, R'₇, R₈, R'₈, R₉, R'₉, M, X, Y, Z and n are defined herein for use as contrast agents in diagnostic imaging.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING METAL
COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS

Background of the Invention

5

This invention relates to compounds effective as contrast agents in diagnostic imaging. In one aspect, this invention relates to magnetic resonance imaging (MRI) of human or non-human animal subjects using metal
10 complexes of substituted nitrogen-containing fifteen-membered macrocyclic ligands as contrast agents. In another aspect, this invention relates to manganese(II) complexes of substituted nitrogen-containing fifteen-membered macrocyclic ligands as MRI contrast agents.

15 X-rays have long been used to produce images of human and non-human animal tissue, e.g. the internal organs of a patient, the patient being positioned between a source of X-rays and a film sensitive to the rays. Where organs interfere with the passage of the
20 rays, the film is less exposed and the resulting developed film is indicative of the state of the organ.

More recently, nuclear magnetic resonance (NMR) has been developed as an imaging technique, i.e. MRI. MRI avoids the harmful effects sometimes attending X-ray
25 exposure. For improved imaging with X-rays, patients have been given enhancers prior to imaging, either orally or parenterally. After a predetermined time interval for distribution of the enhancer through the patient, the image is taken. To obtain a good image it
30 is desirable that the time after the taking of enhancer be kept to a minimum. On the other hand there is a decrease in effectiveness with time, so desirably the decay should be relatively slow so as to provide a substantial time interval during which imaging can be
35 done.

-2-

In the NMR imaging process, protons in the water of the body relax via two mechanisms. The respective relaxation times are referred to as T_1 and T_2 . The rate at which the relaxation process occurs may be altered
5 for some water molecules by giving values that contrast with the norm.

Compounds that enhance NMR images, referred to as contrast agents, are generally paramagnetic in nature. These may be organic free radicals or
10 transition/lanthanide metals which have from one to seven unpaired electrons.

A necessary prerequisite of any ligand that binds a metal to form a contrast agent is that the resulting contrast agent be stable so as to prevent the loss of
15 the metal and its subsequent accumulation in the body. Other considerations include an ability to reversibly bind water, which in turn increases its contrastability and decreases the dose level required. This ability is clearly important since the interaction between any two
20 nuclear spins through space decreases at a rate equal to the reciprocal of the distance raised to the sixth power.

U.S. Pat. No. 4,647,447 discloses use of an NMR image enhancer consisting of the salt of an anion of a
25 complexing acid and a paramagnetic metal anion. A preferred embodiment is the gadolinium chelate of diethylenetriaminepentaacetic acid (Gd DTPA), which is now commercially available from Nycomed Salutar, Inc. under the trade name Magnevist for use as an NMR
30 contrast agent. From the data reported therein these appear to perform well. However, this compound is rapidly excreted by the kidneys, making the timing of the injection extremely critical. Furthermore, there is virtually no uptake by any solid organ, such as the
35 heart, pancreas or liver.

-3-

However, while a number of gadolinium contrast agents are known, there remains the possibility that small amounts of free lanthanides are being released, by decomposition of the agent, into the body. Not being a naturally existing metal in the body, little is known about long term effects.

Other nitrogen-containing macrocyclic ligands have been suggested for use as NMR contrast agents. Jackels, S. C. et al, "Aqueous Proton NMR Relaxation Enhancements by Manganese(II) Macrocyclic Complexes: Structure-Relaxivity Relationships", *Inorg. Chem.*, 31, 234-239 (1992) discloses fifteen-membered nitrogen-containing ring complexes. However, these compounds suffer from being insufficiently stable and/or colored, and as such are inadequate for application as MRI contrast agents.

Therefore, it would be highly desirable to develop alternative contrast agents which avoid one or more of the aforementioned disadvantages.

It has now been discovered that metal complexes of substituted nitrogen-containing macrocyclic ligands which have increased kinetic, thermodynamic and oxidative stability, and which can be substituted to control lipophilicity, i.e. biodistribution, avoid the problems of the aforementioned contrast agents while providing good contrastability.

SUMMARY OF THE INVENTION

It is an object of the invention to provide magnetic resonance imaging (MRI) contrast agents having kinetic stability, i.e. the rate at which the paramagnetic metal dissociates from the metal complexes of the invention. It is a further object of the invention to provide MRI contrast agents in which the biodistribution of the contrast agents can be

-4-

controlled. It is yet a further object of the invention to provide MRI contrast agents having oxidative stability and hydrogen bonding. It is a still further object of the invention to provide metal complexes which are useful as X-ray or ultrasound contrast agents, and which can be used in scintigraphy and radiotherapy.

According to the invention, a method of magnetic resonance imaging is provided which comprises administering to a human or non-human animal subject a contrast medium comprising a physiologically compatible paramagnetic metal complex of the present invention and a non-toxic, pharmaceutically acceptable carrier, adjuvant or vehicle, and generating a magnetic resonance image of at least a part of the subject.

Further according to the invention, a method of diagnostic imaging is provided which comprises administering to a human or non-human animal subject a diagnostic agent comprising a physiologically compatible heavy metal complex of the present invention and a non-toxic, pharmaceutically acceptable carrier, adjuvant or vehicle, and generating an X-ray, ultrasound or scintigraphic image of at least a part of the subject.


Further according to the invention, a method of radiotherapy practiced on a human or non-human animal subject is provided which comprises administering to the subject a radioactive agent comprising a physiologically compatible radioactive metal complex of the present invention and a non-toxic, pharmaceutically acceptable carrier, adjuvant or vehicle.

DETAILED DESCRIPTION OF THE INVENTION

The metal complexes of the invention used as MRI contrast agents, as diagnostic agents in X-ray, ultrasound or scintigraphic image analysis, or as radiotherapy agents are represented by the formula:

-5-

5



10

- wherein at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radicals wherein the substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$, $-O-(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$;
- or at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are independently selected
- wherein one "R" group of the pair is an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl radical and the other "R" group on the adjacent carbon atom of the macrocycle is a substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radical wherein the

-6-

substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$, $-O-(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$; or combinations thereof; wherein R_{10} and R_{11} are independently selected from the group consisting of hydrogen and alkyl groups, and a and b are integers independently selected from 1 to 6; and the remaining "R" groups are hydrogen or, optionally, are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylcycloalkyl, cycloalkenylalkyl, alkylcycloalkyl, alkenylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkenyl, heterocyclic, aryl and aralkyl radicals and radicals attached to the α -carbon of α -amino acids; or R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , R_7 or R'_7 and R_8 or R'_8 , and R_9 or R'_9 and R or R' together with the carbon atoms to which they are attached independently form a saturated, partially saturated or unsaturated cyclic having 3 to 20 carbon atoms; or R or R' and R_1 or R'_1 , R_2 or R'_2 and R_3 or R'_3 , R_4 or R'_4 and R_5 or R'_5 , R_6 or R'_6 and R_7 or R'_7 , and R_8 or R'_8 and R_9 or R'_9 together with the carbon atoms to which they are attached independently form a nitrogen containing heterocycle having 2 to 20 carbon atoms provided that when the nitrogen containing heterocycle is an aromatic heterocycle which does not contain a hydrogen attached to the nitrogen, the hydrogen attached to the nitrogen in said formula, which nitrogen is also in the macrocycle and the R groups attached to the same carbon atoms of the macrocycle are absent; and combinations thereof.

The currently preferred optional "R" groups are alkyl radicals, radicals attached to the α -carbon of

-7-

α -amino acids, and saturated, partially saturated or unsaturated cyclic ring structures having 3 to 20 carbon atoms. Currently, R_{10} and R_{11} are preferably hydrogen.

X, Y and Z represent suitable ligands or charge-
5 neutralizing anions which are derived from any monodentate or polydentate coordinating ligand or ligand system or the corresponding anion thereof (for example benzoic acid or benzoate anion, phenol or phenoxide anion, alcohol or alkoxide anion). X, Y and Z are
10 independently selected from the group consisting of halide, oxo, aquo, hydroxo, alcohol, phenol, dioxygen, peroxy, hydroperoxy, alkylperoxy, arylperoxy, ammonia, alkylamino, arylamino, heterocycloalkyl amino, heterocycloaryl amino, amine oxides, hydrazine, alkyl
15 hydrazine, aryl hydrazine, nitric oxide, cyanide, cyanate, thiocyanate, isocyanate, isothiocyanate, alkyl nitrile, aryl nitrile, alkyl isonitrile, aryl isonitrile, nitrate, nitrite, azido, alkyl sulfonic acid, aryl sulfonic acid, alkyl sulfoxide, aryl
20 sulfoxide, alkyl aryl sulfoxide, alkyl sulfenic acid, aryl sulfenic acid, alkyl sulfinic acid, aryl sulfinic acid, alkyl thiol carboxylic acid, aryl thiol carboxylic acid, alkyl thiol thiocarboxylic acid, aryl thiol thiocarboxylic acid, alkyl carboxylic acid (such
25 as acetic acid, trifluoroacetic acid, oxalic acid), aryl carboxylic acid (such as benzoic acid, phthalic acid), urea, alkyl urea, aryl urea, alkyl aryl urea, thiourea, alkyl thiourea, aryl thiourea, alkyl aryl triourea, sulfate, sulfite, bisulfate, bisulfite, thiosulfate,
30 thiosulfite, hydrosulfite, alkyl phosphine, aryl phosphine, alkyl phosphine oxide, aryl phosphine oxide, alkyl aryl phosphine oxide, alkyl phosphine sulfide, aryl phosphine sulfide, alkyl aryl phosphine sulfide, alkyl phosphonic acid, aryl phosphonic acid, alkyl
35 phosphinic acid, aryl phosphinic acid, alkyl phosphinous acid, aryl phosphinous acid, phosphate, thiophosphate,

-8-

- phosphite, pyrophosphite, triphosphate, hydrogen phosphate, dihydrogen phosphate, alkyl guanidino, aryl guanidino, alkyl aryl guanidino, alkyl carbamate, aryl carbamate, alkyl aryl carbamate, alkyl thiocarbamate
- 5 aryl thiocarbamate, alkyl aryl thiocarbamate, alkyl dithiocarbamate, aryl dithiocarbamate, alkyl aryl dithiocarbamate, bicarbonate, carbonate, perchlorate, chlorate, chlorite, hypochlorite, perbromate, bromate, bromite, hypobromite, tetrahalomanganate,
- 10 tetrafluoroborate, hexafluorophosphate, hexafluoroantimonate, hypophosphite, iodate, periodate, metaborate, tetraaryl borate, tetra alkyl borate, tartrate, salicylate, succinate, citrate, ascorbate, saccharinate, amino acid, hydroxamic acid,
- 15 thiotosylate, and anions of ion exchange resins, or systems where one or more of X,Y and Z are independently attached to one or more of the "R" groups, wherein n is an integer from 0 to 3. The preferred ligands from which X, Y and Z are selected include halide, organic
- 20 acid, nitrate and bicarbonate anions.

The metal atoms or anions, M, which are suitable for use in the complexes of the invention as MRI contrast agents are paramagnetic metals having atomic numbers 21-29, 42-44 and 57-71. The complexes for use

25 as MRI contrast agents are those wherein the preferred metal is Eu, Gd, Dy, Ho, Cr, Mn or Fe, more preferably Gd(III) or Mn(II), and most preferably Mn(II).

The metal atoms or anions, M, which are suitable for use in the complexes of the invention as X-ray or

30 ultrasound contrast agents are heavy metals having atomic numbers 20-32, 42-44, 49 and 57-83. The complexes for use as X-ray or ultrasound contrast agents are those wherein the preferred metal is a non-radioactive metal having atomic numbers 42-44, 49 and

35 57-83, and most preferably Gd, Dy or Yb.

-9-

The metal atoms or anions, M, of the complexes of the invention which are suitable for use in scintigraphic and radiotherapy are radioactive metals of any conventional complexable radioactive metal isotope, preferably those having atomic numbers 20-32, 42-44, 49 and 57-83. In scintigraphy, the most preferred metals are ^{99m}Tc or ^{111}In . In radiotherapy, the most preferred metals are ^{153}Sm , ^{67}Cu or ^{90}Y .

Currently, the preferred compounds are those wherein at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radicals wherein the substituents are independently selected from the group consisting of $-\text{OR}_{10}$, $-\text{NR}_{10}\text{R}_{11}$, $-\text{COR}_{10}$, $-\text{CO}_2\text{R}_{10}$, $-\text{CONR}_{10}\text{R}_{11}$, $-\text{O}(-(\text{CH}_2)_a-\text{O})_b-\text{R}_{10}$, $-\text{SR}_{10}$, $-\text{SOR}_{10}$, $-\text{SO}_2\text{R}_{10}$, $-\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $-\text{N}(\text{OR}_{10})(\text{R}_{11})$, $-\text{P}(\text{O})(\text{OR}_{10})(\text{OR}_{11})$, $-\text{P}(\text{O})(\text{OR}_{10})(\text{R}_{11})$ and $-\text{OP}(\text{O})(\text{OR}_{10})(\text{OR}_{11})$, more preferably $-\text{OR}_{10}$ or $-\text{NR}_{10}\text{R}_{11}$, and most preferably $-\text{OR}_{10}$; and the remaining "R" groups are hydrogen or, optionally, are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylcycloalkyl, cycloalkenylalkyl, alkylcycloalkyl, alkenylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkenyl, heterocyclic, aryl and aralkyl radicals and radicals attached to the α -carbon of α -amino acids; or R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , R_7 or R'_7 and R_8 or R'_8 , and R_9 or R'_9 and R or R' together with the carbon atoms to which they are attached independently form a saturated, partially saturated or unsaturated cyclic having 3 to 20 carbon atoms; or R or R' and R_1 or R'_1 , R_2 or R'_2 and R_3 or R'_3 , R_4 or R'_4 and

-10-

R_5 or R'_5 , R_6 or R'_6 and R_7 or R'_7 , and R_8 or R'_8 and R_9 or R'_9 together with the carbon atoms to which they are attached independently form a nitrogen containing heterocycle having 2 to 20 carbon atoms provided that
 5 when the nitrogen containing heterocycle is an aromatic heterocycle which does not contain a hydrogen attached to the nitrogen, the hydrogen attached to the nitrogen in said formula, which nitrogen is also in the macrocycle and the R groups attached to the same carbon
 10 atoms of the macrocycle are absent; and combinations thereof. Even more preferred are compounds wherein the "R" groups of the at least one pair of "R" groups on adjacent carbon atoms of the macrocycle are substituted alkyl groups, and the substituents are preferably $-OR_{10}$
 15 and more preferably $-OH$.

Another preferred group of compounds are those wherein at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or
 20 R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are independently selected wherein one "R" group of the pair is an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl radical and the other "R" group on the adjacent carbon atom of the
 25 macrocycle is a substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radical wherein the substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$,
 30 $-O(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$, more preferably $-OR_{10}$ or $-NR_{10}R_{11}$, and most preferably $-OR_{10}$; and the remaining "R" groups are hydrogen or, optionally, are independently selected from
 35 the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl,





-11-

- cycloalkylcycloalkyl, cycloalkenylalkyl,
alkylcycloalkyl, alkenylcycloalkyl, alkylcycloalkenyl,
alkenylcycloalkenyl, heterocyclic, aryl and aralkyl
radicals and radicals attached to the α -carbon of
- 5 α -amino acids; or R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and
 R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , R_7 or R'_7 and R_8 or
 R'_8 , and R_9 or R'_9 and R or R' together with the carbon
atoms to which they are attached independently form a
saturated, partially saturated or unsaturated cyclic
- 10 having 3 to 20 carbon atoms; or R or R' and R_1 or R'_1 , R_2
or R'_2 and R_3 or R'_3 , R_4 or R'_4 and R_5 or R'_5 , R_6 or R'_6
and R_7 or R'_7 , and R_8 or R'_8 and R_9 or R'_9 together with
the carbon atoms to which they are attached
independently form a nitrogen containing heterocycle
- 15 having 2 to 20 carbon atoms provided that when the
nitrogen containing heterocycle is an aromatic
heterocycle which does not contain a hydrogen attached
to the nitrogen, the hydrogen attached to the nitrogen
in said formula, which nitrogen is also in the
- 20 macrocycle and the R groups attached to the same carbon
atoms of the macrocycle are absent; and combinations
thereof. Even more preferred are compounds wherein one
"R" group of the at least one pair of "R" groups on
adjacent carbon atoms of the macrocycle is an alkyl
- 25 group and the other "R" group on the adjacent carbon
atom of the macrocycle is a substituted alkyl group, and
the substituent on the carbon atom of the at least one
pair of "R" groups on adjacent carbon atoms of the
macrocycle which is a substituted group is $-OR_{10}$, and
- 30 more preferably $-OH$.



As used herein, "R" groups means all of the R
groups attached to the carbon atoms of the macrocycle,
i.e., R , R' , R_1 , R'_1 , R_2 , R'_2 , R_3 , R'_3 , R_4 , R'_4 , R_5 , R'_5 ,
 R_6 , R'_6 , R_7 , R'_7 , R_8 , R'_8 , R_9 and R'_9 . Examples of

35 complexes of the invention include, but are not limited
to, compounds having the formulas:


-12-



-13-




As utilized herein, the term "alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing from 1 to about 22 carbon atoms, preferably from about 1 to about 18 carbon atoms, and most preferably from about 1 to about 12 carbon atoms which optionally carries one or more substituents selected from (1) $-NR_{30}R_{31}$ wherein R_{30} and R_{31} are independently selected from hydrogen, alkyl, aryl or aralkyl ; or R_{30} is hydrogen, alkyl, aryl or aralkyl and R_{31} is selected from the group consisting of $-NR_{32}R_{33}$, $-OH$, $-OR_{34}$,




wherein R_{32} and R_{33} are independently hydrogen, alkyl, aryl or acyl, R_{34} is alkyl, aryl or alkaryl, Z' is

-14-


- hydrogen, alkyl, aryl, alkaryl, $-\text{OR}_{34}$, $-\text{SR}_{34}$ or $-\text{NR}_{40}\text{R}_{41}$ wherein R_{40} and R_{41} are independently selected from hydrogen, alkyl, aryl or alkaryl, Z'' is alkyl, aryl, alkaryl, $-\text{OR}_{34}$, $-\text{SR}_{34}$ or $-\text{NR}_{40}\text{R}_{41}$, R_{35} is alkyl, aryl, $-\text{OR}_{34}$, or $-\text{NR}_{40}\text{R}_{41}$, R_{36} is alkyl, aryl or $-\text{NR}_{40}\text{R}_{41}$, R_{37} is alkyl, aryl or alkaryl, X' is oxygen or sulfur, and R_{38} and R_{39} are independently selected from hydrogen, alkyl or aryl;
- (2) $-\text{SR}_{42}$ wherein R_{42} is hydrogen, alkyl, aryl, alkaryl, $-\text{SR}_{34}$, $-\text{NR}_{32}\text{R}_{33}$,




wherein R_{43} is $-\text{OH}$, $-\text{OR}_{34}$ or $-\text{NR}_{32}\text{R}_{33}$, and A and B are independently $-\text{OR}_{34}$, $-\text{SR}_{34}$ or $-\text{NR}_{32}\text{R}_{33}$;



- (3)
- 15 wherein x is 1 or 2, and R_{44} is alkyl, aryl, alkaryl, $-\text{OH}$, $-\text{OR}_{34}$, $-\text{SR}_{34}$ or $-\text{NR}_{32}\text{R}_{33}$;
- (4) $-\text{OR}_{45}$ wherein R_{45} is hydrogen, alkyl, aryl, alkaryl, $-\text{NR}_{32}\text{R}_{33}$,




wherein D and E are independently $-\text{OR}_{34}$ or $-\text{NR}_{32}\text{R}_{33}$;



(5)


wherein R_{46} is $-\text{OH}$, $-\text{SH}$, $-\text{OR}_{34}$, $-\text{SR}_{34}$ or $-\text{NR}_{32}\text{R}_{33}$; or

-15-



(6) amine oxides of the formula provided R_{30}

and R_{31} are not hydrogen; or



(7)

- wherein F and G are independently -OH, -SH, -OR₃₄, -SR₃₄
 5 or -NR₃₂R₃₃; or
- (8) halogen, cyano, nitro, or azido. Alkyl, aryl and
 alkaryl groups on the substituents of the above-defined
 alkyl groups may contain one additional substituent but
 are preferably unsubstituted. Examples of such radicals
 10 include, but are not limited to, methyl, ethyl,
 n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-
 butyl, pentyl, isoamyl, hexyl, octyl, nonyl, decyl,
 dodecyl, tetradecyl, hexadecyl, octadecyl and eicosyl.
 The term "alkenyl", alone or in combination, means an
 15 alkyl radical having one or more double bonds. Examples
 of such alkenyl radicals include, but are not limited
 to, ethenyl, propenyl, 1-butenyl, cis-2-butenyl, trans-
 2-butenyl, iso-butylenyl, cis-2-pentenyl, trans-2-
 pentenyl, 3-methyl-1-butenyl, 2,3-dimethyl-2-butenyl,
 20 1-pentenyl, 1-hexenyl, 1-octenyl, decenyl, dodecenyl,
 tetradecenyl, hexadecenyl, cis- and trans-
 9-octadecenyl, 1,3-pentadienyl, 2,4-pentadienyl,
 2,3-pentadienyl, 1,3-hexadienyl, 2,4-hexadienyl,
 5,8,11,14-eicosatetraenyl, and 9,12,15-octadecatrienyl.
 25 The term "alkynyl", alone or in combination, means an
 alkyl radical having one or more triple bonds. Examples
 of such alkynyl groups include, but are not limited to,
 ethynyl, propynyl (propargyl), 1-butyne, 1-octynyl,
 9-octadecynyl, 1,3-pentadiynyl, 2,4-pentadiynyl, 1,3-
 30 hexadiynyl, and 2,4-hexadiynyl. The term "cycloalkyl",

-16-

alone or in combination means a cycloalkyl radical containing from 3 to about 10, preferably from 3 to about 8, and most preferably from 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include, 5 but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and perhydronaphthyl. The term "cycloalkylalkyl" means an alkyl radical as defined above which is substituted by a cycloalkyl radical as defined above. Examples of 10 cycloalkylalkyl radicals include, but are not limited to, cyclohexylmethyl, cyclopentylmethyl, (4-isopropylcyclohexyl)methyl, (4-*t*-butyl-cyclohexyl)methyl, 3-cyclohexylpropyl, 2-cyclo-hexylmethylnpentyl, 15 3-cyclopentylmethylnhexyl, 1-(4-neopentylcyclohexyl)methylhexyl, and 1-(4-isopropylcyclohexyl)methylheptyl. The term "cycloalkylcycloalkyl" means a cycloalkyl radical as defined above which is substituted by another cycloalkyl 20 radical as defined above. Examples of cycloalkylcycloalkyl radicals include, but are not limited to, cyclohexylcyclopentyl and cyclohexylcyclohexyl. The term "cycloalkenyl", alone or in combination, means a cycloalkyl radical having one or 25 more double bonds. Examples of cycloalkenyl radicals include, but are not limited to, cyclopentenyl, cyclohexenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl and cyclooctadienyl. The term "cycloalkenylalkyl" means an alkyl radical as defined 30 above which is substituted by a cycloalkenyl radical as defined above. Examples of cycloalkenylalkyl radicals include, but are not limited to, 2-cyclohexen-1-ylmethyl, 1-cyclopenten-1-ylmethyl, 2-(1-cyclohexen-1-yl)ethyl, 35 3-(1-cyclopenten-1-yl)propyl, 1-(1-cyclohexen-1-ylmethyl)pentyl, 1-(1-cyclopenten-1-yl)hexyl,

-17-

6-(1-cyclohexen-1-yl)hexyl, 1-(1-cyclopenten-1-yl)nonyl and 1-(1-cyclohexen-1-yl)nonyl. The terms "alkylcycloalkyl" and "alkenylcycloalkyl" mean a cycloalkyl radical as defined above which is substituted
5 by an alkyl or alkenyl radical as defined above. Examples of alkylcycloalkyl and alkenylcycloalkyl radicals include, but are not limited to, 2-ethylcyclobutyl, 1-methylcyclopentenyl, 1-hexylcyclopentyl, 1-methylcyclohexyl,
10 1-(9-octadecenyl)cyclopentyl and 1-(9-octadecenyl)cyclohexyl. The terms "alkylcycloalkenyl" and "alkenylcycloalkenyl" means a cycloalkenyl radical as defined above which is substituted by an alkyl or alkenyl radical as defined
15 above. Examples of alkylcycloalkenyl and alkenylcycloalkenyl radicals include, but are not limited to, 1-methyl-2-cyclopentenyl, 1-hexyl-2-cyclopentenyl, 1-ethyl-2-cyclohexenyl, 1-butyl-2-cyclohexenyl, 1-(9-octadecenyl)-2-cyclohexenyl
20 and 1-(2-pentenyl)-2-cyclohexenyl. The term "aryl", alone or in combination, means a phenyl or naphthyl radical which optionally carries one or more substituents selected from alkyl, cycloalkyl, cycloalkenyl, aryl, heterocycle, alkoxyaryl, alkaryl, alkoxy, halogen, hydroxy, amine, cyano, nitro,
25 alkylthio, phenoxy, ether, trifluoromethyl and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like.
30 The term "aralkyl", alone or in combination, means an alkyl or cycloalkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl, and the like. The term "heterocyclic" means ring structures
35 containing at least one other kind of atom, in addition to carbon, in the ring. The most common of the other

-18-

kinds of atoms include nitrogen, oxygen and sulfur. Examples of heterocyclics include, but are not limited to, pyrrolidinyl, piperidyl, imidazolidinyl, tetrahydrofuryl, tetrahydrothienyl, furyl, thienyl, 5 pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrazinyl, indolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, benzoxadiazolyl, benzothiadiazolyl, triazolyl and tetrazolyl groups. The term "saturated, partially saturated or unsaturated cyclic" means fused ring 10 structures in which 2 carbons of the ring are also part of the fifteen-membered macrocyclic ligand. The ring structure can contain 3 to 20 carbon atoms, preferably 5 to 10 carbon atoms, and can also contain one or more other kinds of atoms in addition to carbon. The most 15 common of the other kinds of atoms include nitrogen, oxygen and sulfur. The ring structure can also contain more than one ring. The term "saturated, partially saturated or unsaturated ring structure" means a ring structure in which one carbon of the ring is also part 20 of the fifteen-membered macrocyclic ligand. The ring structure can contain 3 to 20, preferably 5 to 10, carbon atoms and can also contain nitrogen, oxygen and/or sulfur atoms. The term "nitrogen containing heterocycle" means ring structures in which 2 carbons 25 and a nitrogen of the ring are also part of the fifteen-membered macrocyclic ligand. The ring structure can contain 2 to 20, preferably 4 to 10, carbon atoms, can be partially or fully unsaturated or saturated and can also contain nitrogen, oxygen and/or sulfur atoms in the 30 portion of the ring which is not also part of the fifteen-membered macrocyclic ligand. The term "organic acid anion" refers to carboxylic acid anions having from about 1 to about 18 carbon atoms. The term "halide" means chloride or bromide.

-19-

The overall charge-type of the complex can be varied from negative to positive by carbon substitution of the appropriate charged groups on the macrocyclic framework. While the manganese (II) complexes of the invention exist as monocations in methanol solution, the axial anions are labile and in vivo can rapidly exchange with endogenous charged or uncharged ligands. By considering the dipositive nature of the manganese (II) metal center, the overall charge on the complex can be adjusted as needed to enhance desired pharmaceutical properties such as osmolality, tissue distribution and non-target clearance. For example, if the complex carries only charge neutral functionality, such as C-alkyl substitution, then the overall charge on the complex will be determined by the manganese center and will be positive. Multi-positive complexes are available via the incorporation of pendant cations such as protonated aminoalkyl groups. These types of complexes can bind to endogenous anions, anionic proteins, cell membranes, and the like. If two pendant anionic groups are attached, such as two carboxylates, phenolate, phosphonates, sulfonates and the like, the overall charge on the complex can be envisioned as zero. Alternatively, if three or more pendant anionic groups are attached, then an anionic complex will result. The pendant groups may be designed to axially chelate and formally displace the axial anions or they may be designed specifically to not chelate but retain a charge type.

The substituents on the complex of the invention, i.e. the "R" groups other than hydrogen, are those groups which result in complexes having improved stability, controlled lipophilicity, improved hydrogen bonding and greater rigidity of the macrocyclic ligand.

Regarding rigidity of the macrocycle, groups which rigidify the macrocycle typically result in

-20-

improved stability and improved inner- and outer-sphere relaxation. Examples of groups which improve rigidity of the macrocycle include, but are not limited to, cycloalkyl groups e.g. trans-cyclohexano, and multiple
5 alkyl or substituted alkyl groups.

Regarding hydrogen bonding, groups that improve hydrogen bonding result in improved residence time of water to the metal complex by providing alternate binding sites. Examples of groups that improve hydrogen
10 bonding include, but are not limited to, hydroxy alkyl or amino alkyl, e.g. hydroxymethyl or aminopropyl.

By varying the type and number of substituents, e.g. "R" groups which are other than hydrogen, the lipophilicity of the complexes can be controlled, i.e.
15 the biodistribution of the complexes of the invention can be controlled, by preparing compounds which vary from hydrophilic to lipophilic. Therefore, the complexes of the invention can be targeted to various tissues or organs in the body by controlling the type
20 and number of substituents.

Kinetic stability of the metal complex is important because complexes which are not sufficiently kinetically stable dissociate and release free metal in the body. The kinetic stability, k_{diss} ($\text{M}^{-1}\text{sec}^{-1}$), can be
25 controlled by varying the type and number of substituents which are other than hydrogen. Oxidative stability of the metal complex is a particular problem for Mn complexes and is important because complexes which are not sufficiently oxidatively stable will go
30 from Mn(II) to Mn(III). Since the Mn(III) complexes are colored, it is necessary to maintain the complexes in the Mn(II) form to have a suitable contrast agent. By varying the type and number of substituents, the oxidative stability, $E_{1/2}(\text{v})$, is controlled. It is
35 generally desired to select the type and number of substituents such that $E_{1/2}$ is greater than about 0.7v.

-21-


A first embodiment of the invention relates to a method of magnetic resonance imaging comprising (a) administering to a human or non-human animal subject a contrast medium comprising a physiologically compatible complex of the invention and a nontoxic pharmaceutically acceptable carrier, adjuvant or vehicle; and (b) generating a magnetic resonance image of at least a part of the human or non-human animal subject.

10 A second embodiment of the invention relates to a method of diagnostic imaging comprising (a) administering to a human or non-human animal subject a diagnostic agent comprising a physiologically compatible complex of the present invention and a
15 nontoxic, pharmaceutically acceptable carrier, adjuvant or vehicle, and (b) generating an X-ray, ultrasound or scintigraphic image of at least a part of the human or non-human animal subject.

A third embodiment of the invention relates to a
20 method of radiotherapy practiced on a human or non-human animal subject comprising administering to the human or non-human animal subject a radioactive agent comprising a physiologically compatible complex of the present invention wherein M is a radioactive metal, and a
25 nontoxic, pharmaceutically acceptable carrier, adjuvant or vehicle.

The macrocyclic ligands useful in the complexes of the present invention can be prepared according to the general procedure shown in Scheme A set forth below.
30 Thus, an amino acid amide, which is the corresponding amide derivative of a naturally or non-naturally occurring α -amino acid, is reduced to form the corresponding substituted ethylenediamine. Such amino acid amide can be the amide derivative of any one of
35 many well known amino acids. Preferred amino acid amides are those represented by the formula:

-22-



- 5 wherein R is derived from the D or L forms of the amino acids Alanine, Aspartic acid, Arginine, Asparagine, Cysteine, Glycine, Glutamic acid, Glutamine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Proline, Phenylalanine, Serine, Tryptophan, Threonine, Tyrosine,
- 10 Valine and /or the R groups of unnatural α -amino acids such as alkyl, ethyl, butyl, tert-butyl, cycloalkyl, phenyl, alkenyl, allyl, alkynyl, aryl, heteroaryl, polycycloalkyl, polycycloaryl, polycycloheteroaryl, imines, aminoalkyl, hydroxyalkyl, hydroxyl, phenol,
- 15 amine oxides, thioalkyl, carboalkoxyalkyl, carboxylic acids and their derivatives, keto, ether, aldehyde, amine, nitrile, halo, thiol, sulfoxide, sulfone, sulfonic acid, sulfide, disulfide, phosphonic acid, phosphinic acid, phosphine oxides, sulfonamides, amides,
- 20 amino acids, peptides, proteins, carbohydrates, nucleic acids, fatty acids, lipids, nitro, hydroxylamines, hydroxamic acids, thiocarbonyls, borates, boranes, boraza, silyl, siloxy, silaza, and combinations thereof. Most preferred are those wherein R represents hydrogen,
- 25 alkyl, cycloalkylalkyl, and aralkyl radicals. The diamine is then tosylated to produce the di-N-tosyl derivative which is reacted with a di-O-tosylated tris-N-tosylated triazaalkane diol to produce the corresponding substituted
- 30 N-pentatosylpentaazacycloalkane. The tosyl groups are then removed and the resulting compound is reacted with a metal compound, e.g. a manganese(II) compound, under essentially anhydrous and anaerobic conditions to form the corresponding substituted metal, e.g. manganese(II),
- 35 pentaazacycloalkane complex. When the ligands or

-23-

charge-neutralizing anions, i.e. X, Y and Z, are anions or ligands that cannot be introduced directly from the metal, e.g. manganese, compound, the complex with those anions or ligands can be formed by conducting an
5 exchange reaction with a complex that has been prepared by reacting the macrocycle with a metal, e.g. manganese, compound.

The complexes of the present invention, wherein R_9 , and R_2 are alkyl, and R_3 , R'_3 , R_4 , R'_4 , R_5 , R'_5 , R_6 ,
10 R'_6 , R_7 , R'_7 , R_8 and R'_8 can be alkyl, arylalkyl or cycloalkylalkyl and R or R' and R_1 or R'_1 together with the carbon atoms they are attached to are bound to form a nitrogen containing heterocycle, can also be prepared according to the general procedure shown in Scheme B set
15 forth below utilizing methods known in the art for preparing the metal, e.g. manganese(II), pentaazabicyclo[12.3.1]octadecapentaene complex precursor. See, for example, Alexander et al., Inorg. Nucl. Chem. Lett., 6, 445 (1970). Thus a
20 2,6-diketopyridine is condensed with triethylene tetraamine in the presence of a metal, e.g. manganese(II), compound to produce the metal, e.g. manganese(II), pentaazabicyclo[12.3.1]octadecapentaene complex. The metal, e.g. manganese(II),
25 pentaazabicyclo[12.3.1]octadecapentaene complex is hydrogenated with platinum oxide at a pressure of 10-1000 psi to give the corresponding metal, e.g. manganese(II), pentaazabicyclo[12.3.1]octadecatriene complex.

30 The macrocyclic ligands useful in the complexes of the present invention can also be prepared by the diacid dichloride route shown in Scheme C set forth below. Thus, a triazaalkane is tosylated in a suitable solvent system to produce the corresponding tris
35 (N-tosyl) derivative. Such a derivative is treated with a suitable base to produce the corresponding

-24-

disulfonamide anion. The disulfonamide anion is dialkylated with a suitable electrophile to produce a derivative of a dicarboxylic acid. This derivative of a dicarboxylic acid is treated to produce the dicarboxylic acid, which is then treated with a suitable reagent to form the diacid dichloride. The desired vicinal diamine is obtained in any of several ways. One way which is useful is the preparation from an aldehyde by reaction with cyanide in the presence of ammonium chloride followed by treatment with acid to produce the alpha ammonium nitrile. The latter compound is reduced in the presence of acid and then treated with a suitable base to produce the vicinal diamine. Condensation of the diacid dichloride with the vicinal diamine in the presence of a suitable base forms the tris(tosyl)diamide macrocycle. The tosyl groups are removed and the amides are reduced and the resulting compound is reacted with a metal, e.g. manganese (II), compound under essentially anhydrous and anaerobic conditions to form the corresponding substituted pentaazacycloalkane metal, e.g. manganese (II), complex.

The vicinal diamines have been prepared by the route shown (known as the Strecker synthesis) and vicinal diamines were purchased when commercially available. Any method of vicinal diamine preparation could be used.

The macrocyclic ligands useful in the complexes of the present invention can also be prepared by the pyridine diamide route shown in Scheme D as set forth below. Thus, a polyamine, such as a tetraaza compound, containing two primary amines is condensed with dimethyl 2,6-pyridine dicarboxylate by heating in an appropriate solvent, e.g., methanol, to produce a macrocycle incorporating the pyridine ring as the 2,6-dicarboxamide. The pyridine ring in the macrocycle is reduced to the corresponding piperidine ring in the


-25-

macrocycle, and then the diamides are reduced and the resulting compound is reacted with a metal, e.g. manganese (II), compound under essentially anhydrous and anaerobic conditions to form the corresponding substituted pentaazacycloalkane metal, e.g. manganese (II), complex.

The macrocyclic ligands useful in the complexes of the present invention can also be prepared by the bis(haloacetamide) route shown in Scheme E set forth below. Thus a triazaalkane is tosylated in a suitable solvent system to produce the corresponding tris (N-tosyl) derivative. Such a derivative is treated with a suitable base to produce the corresponding disulfonamide anion. A bis(haloacetamide), e.g., a bis(chloroacetamide), of a vicinal diamine is prepared by reaction of the diamine with an excess of haloacetyl halide, e.g., chloroacetyl chloride, in the presence of a base. The disulfonamide anion of the tris(N-tosyl) triazaalkane is then reacted with the bis(chloroacetamide) of the diamine to produce the substituted tris(N-tosyl)diamide macrocycle. The tosyl groups are removed and the amides are reduced and the resulting compound is reacted with a metal, e.g. manganese (II), compound under essentially anhydrous and anaerobic conditions to form the corresponding substituted pentaazacycloalkane metal, e.g. manganese (II), complex.

The macrocyclic ligands useful in the complexes of the present invention, wherein R_1, R'_1, R_2, R'_2 are derived from a diamino starting material and R_5, R'_5, R_7, R'_7 and R_9, R'_9 can be H or any functionality previously described, can be prepared according to the pseudo-peptide method shown in Scheme F set forth below. A substituted 1,2-diaminoethane represented by the formula

-26-



, wherein R_1 , R_1' , R_2 and R_2' are the substituents on adjacent carbon atoms in the product macrocyclic ligand as set forth above, can be used in this method in combination with any amino acids. The diamine can be produced by any conventional method known to those skilled in the art. The R groups in the macrocycle derived from substituents on the α -carbon of α -amino acids, i.e. R_5 , R_5' , R_7 , R_7' , R_9 and R_9' , could be derived from the D or L forms of the amino acids Alanine, Aspartic acid, Arginine, Asparagine, Cysteine, Glycine, Glutamic acid, Glutamine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Proline, Phenylalanine, Serine, Tryptophan, Threonine, Tyrosine, Valine and /or the R groups of unnatural α -amino acids such as alkyl, ethyl, butyl, tert-butyl, cycloalkyl, phenyl, alkenyl, allyl, alkynyl, aryl, heteroaryl, polycycloalkyl, polycycloaryl, polycycloheteroaryl, imines, aminoalkyl, hydroxyalkyl, hydroxyl, phenol, amine oxides, thioalkyl, carboalkoxyalkyl, carboxylic acids and their derivatives, keto, ether, aldehyde, amine, nitrile, halo, thiol, sulfoxide, sulfone, sulfonic acid, sulfide, disulfide, phosphonic acid, phosphinic acid, phosphine oxides, sulfonamides, amides, amino acids, peptides, proteins, carbohydrates, nucleic acids, fatty acids, lipids, nitro, hydroxylamines, hydroxamic acids, thiocarbonyls, borates, boranes, boraza, silyl, siloxy, silaza, and combinations thereof.


As an example 1,8-dihydroxy, 4,5-diaminooctane is monotosylated and reacted with Boc anhydride to afford

-27-

the differentiated N-Boc, N-tosyl derivative. The sulfonamide was alkylated with methyl bromoacetate using sodium hydride as the base and saponified to the free acid. The diamine containing N-tosylglycine serves as a dipeptide surrogate in standard solution-phase peptide synthesis. Thus, coupling with a functionalized amino acid ester affords the corresponding pseudo-tripeptide. Two sequential TFA cleavage-couplings affords the pseudo-pentapeptide which can be N- and C-terminus deprotected in one step using HCl/AcOH. DPPA mediated cyclization followed by LiAlH_4 or Borane reduction affords the corresponding macrocyclic ligand. This ligand system is reacted with a metal, e.g. manganese (II), compound, such as manganese (II) chloride under essentially anaerobic conditions to form the corresponding functionalized manganese (II) pentaazacycloalkane complex. When the ligands or charge-neutralizing anions, i.e. X, Y and Z, are anions or ligands that cannot be introduced directly from the metal, e.g. manganese, compound, the complex with those anions or ligands can be formed by conducting an exchange reaction with a complex that has been prepared by reacting the macrocycle with a metal, e.g. manganese, compound.


25

-28-




-29-

SCHEME B




-30-

SCHEME C




-31-




-32-

Scheme E




-33-

SCHEME F



-34-

SCHEME F (cont.)



-35-

The pentaazamacrocycles of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or nonracemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting one or more secondary amine group(s) of the compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure ligand. The optically active compounds of the invention can likewise be obtained by utilizing optically active starting materials, such as natural amino acids.

The methods of diagnostic analysis of the present invention involve administering the complexes, i.e. contrast enhancing agents, of the invention to a human or non-human animal subject or host, in an amount sufficient to effect the desired contrast (or shift) and then subjecting the host to diagnostic analysis. Preferably diagnostic analysis is NMR analysis;

-36-

including and especially preferred, NMR imaging analysis (or MRI). Further, the complexes of the present invention are useful in diagnostic analysis by X-ray image analysis, ultrasonic analysis or scintigraphic analysis. While described primarily as contrast enhancing agents, the complexes of the invention can act as NMR shift reagents and such use is contemplated by the methods herein.

The complexes of the invention used as contrast enhancing agents are administered in an amount sufficient to effect the desired contrast. For NMR, this amount is an NMR signal effecting amount of the complex, i.e. any amount of said complex that will alter the spin-lattice, spin-spin or spin-echo relaxation times of an NMR signal or for a shift reagent, selectively shift the spectral position of a resonance nucleus relative to other similar nuclei. This alteration is effected in a manner in order to enhance the signals received from the subject under analysis either by reducing the aforementioned relaxation times or by increasing them with respect to an area of the host or the host per se which has had the complex administered to it. In another embodiment, the NMR signal effecting amount of the complex is that amount which in addition to changing the relaxation times of the NMR signals in the host, will also change such relaxation times sufficiently so that sharper lines of definition or higher contrast is obtained between those parts of the host that have and have not been administered the complex.

The relaxation time T_1 (called the spin-lattice) measures the rate at which magnetic energy is transferred from the resonance nuclei to all other energetic degrees of freedom excluding other resonance nuclei. The relaxation time T_2 (spin-spin) measures the

-37-

rate of magnetization transfer to other resonance nuclei.

Another parameter which can be measured is the density ρ of the protons in the medium. As a first
5 approximation, it represents the quantity of free water contained in the sample.

The image by nuclear magnetic resonance represented the distribution of these parameters ρ , T_1 , T_2 or their combination. The contrast between a given
10 tissue and the adjacent tissues increases as a function of the tissues containing more or less water or mobile protons and differing relaxation times. It is also possible to modify the contrast by varying one or more of these parameters (experimentally echoes of spins
15 aiding the function of T_2 , or reversal-recovery of the magnetization permitting the local measurement of T_1). Experience has shown that it was of greater interest to modify the relaxation time to improve the contrast of the image which can be accomplished, for example, with
20 the contrast enhancing agents provided herein. The density of the protons (in practice those of water and lipids) varies little between individual organs and often less between normal and pathological tissues. However, the relaxation characteristics are dependent on
25 a larger number of factors (microscopic dynamics of the molecules, chemical exchange, paramagnetic disturbances, etc.) which are much more variable.

A detailed discussion of NMR and theoretical considerations in selecting the appropriate parameters
30 for diagnostic analysis, e.g. MRI, is rendered in U.S. Pat. No. 4,749,560 which is incorporated herein by reference. X-ray image analysis, ultrasonic diagnosis, scintigraphic image analysis and radiotherapy utilizing the complexes of the invention are all conducted in
35 accordance with well-established techniques known to those of ordinary skill in the art.

-38-

Moreover, the method of diagnostic analysis of the invention allows tissue or organ-specific diagnostic analysis to be achieved. For example, the contrast enhancing agents can exhibit organ and tissue
5 specificity, e.g. biodifferential distribution, such as in myocardial tissue when the complexes of the invention are lipophilic in nature.

The complexes of the invention may be administered to a host as a pharmaceutical composition
10 in a contrast-enhancing amount. The pharmaceutical compositions contain a contrast-enhancing dosage of the contrast agents according to the invention together with a nontoxic pharmaceutically acceptable carrier, adjuvant or vehicle. The compositions can be administered by
15 well-known routes including oral, intravenous (if soluble), intramuscular, intranasal, intradermal, subcutaneous, parenteral, enteral and the like. Depending on the route of administration, the pharmaceutical composition may require protective
20 coatings.

The pharmaceutical forms suitable for injectable use includes sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all
25 cases the ultimate solution form must be sterile and fluid. Typical carriers include a solvent or dispersion medium containing, for example, water, buffered aqueous solutions (i.e. biocompatible buffers), ethanol, polyol (glycerol, propylene glycol, polyethylene glycol, and
30 the like), suitable mixtures thereof, surfactants or vegetable oils. Sterilization can be accomplished by any art recognized technique, including but not limited to, addition of antibacterial or antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid,
35 thimerosal, and the like. Further, isotonic agents,

-39-

such as sugars or sodium chloride may be incorporated in the subject compositions.

Production of sterile injectable solutions containing the subject contrast agent is accomplished by incorporating these agents in the required amount in the appropriate solvent with various ingredients enumerated above, as required, followed by sterilization, preferably filter sterilization. To obtain a sterile powder, the above solutions are vacuum-dried or freeze-dried as necessary.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, granules and gels. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluent, e.g. lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluent commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The contrast agents of the inventions are thus compounded for convenient and effective administration in pharmaceutically effective amounts with a suitable pharmaceutically acceptable carrier, adjuvant or vehicle in a dosage which effects contrast enhancement. These amounts are preferably about 1 μmol to 1 mol of the contrast agent per liter and/or administered in doses of about 0.001 to 5 mmol/kg body weight. Preferred

-40-

compositions provide effective dosages of contrast agents in the range of about 0.001-5 mmol/kg for NMR diagnostics, preferably about 0.005-0.5 mmol/kg; in the range of about 0.1-5 mmol/kg for X-ray diagnostics; and
5 in the range of about 0.1-5 mmol/kg for ultrasound diagnostics. For scintigraphic diagnostics, the dose of the contrast agent should generally be lower than for NMR diagnostics, e.g. MRI. For radiotherapy, conventional doses known to those of ordinary skill in
10 the art can be used.

As used herein, a pharmaceutically acceptable carrier, adjuvant or vehicle includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and the like. The
15 use of such media and agents are well known in the art.

Contemplated equivalents of the general formulas set forth above for the compounds and derivatives as well as the intermediates are compounds otherwise corresponding thereto and having the same general
20 properties such as tautomers of the compounds and such as wherein one or more of the various R groups are simple variations of the substituents as defined therein, e.g., wherein R is a higher alkyl group than that indicated, or where the tosyl groups are other
25 nitrogen or oxygen protecting groups or wherein the O-tosyl is a halide. Anions having a charge other than 1, e.g., carbonate, phosphate, and hydrogen phosphate, can be used instead of anions having a charge of 1, so long as they do not adversely affect the overall
30 activity of the complex. However, using anions having a charge other than 1 will result in a slight modification of the general formula for the complex set forth above. In addition, where a substituent is designated as, or can be, a hydrogen, the exact chemical nature of a
35 substituent which is other than hydrogen at that position, e.g., a hydrocarbyl radical or a halogen,

-41-

hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.

The chemical reactions described above are
5 generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this
10 occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to
15 alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all
20 preparative methods, all starting materials are known or readily preparable from known starting materials.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its
25 fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

30

EXAMPLES

All reagents were used as received without purification unless otherwise indicated. All NMR spectra were obtained on a Varian VXR-300 or VXR-400
35 nuclear magnetic resonance spectrometer. Qualitative

-42-

and quantitative mass spectroscopy was run on a Finnigan MAT90, a Finnigan 4500 and a VG40-250T using m-nitrobenzyl alcohol(NBA), m-nitrobenzyl alcohol/LiCl (NBA - Li) or m-nitrobenzyl alcohol (NBA - HC). Melting
5 points (mp) are uncorrected.

The following abbreviations are in accordance with common usage.

	DMSO	Dimethylsulfoxide
10	THF	Tetrahydrofuran
	DMF	Dimethylformamide

Example 1

15 Synthesis of [Manganese(II) dichloro⁻(trans-2,3-bis(3-hydroxypropyl)-1,4,7,10,13-pentaazacyclopentadecane)]

1.A. Synthesis of D,L-4,5-Diamino-1,7-octadiene

D,L-4,5-Diamino-1,7-octadiene was prepared
20 according to (1) with the following modifications:
D,L-4,5-bis(diphenylmethylamino)-1,7-octadiene (76.2 g, 161 mmol) was dissolved in trifluoroacetic acid (150 ml) under a dry argon atmosphere and triethylsilane (75.0 g, 645 mmol) was then added. The red-brown solution was
25 refluxed for 30 minutes and the solvent was removed in vacuo. The residue was dissolved in 1N HCl (500 ml) and concentrated to a volume of 200 ml in vacuo. Then, 1N HCl (800 ml) was added and the solution was washed with CH₂Cl₂ (3 x 500 ml) and ethyl ether (500 ml). The
30 solvent was removed in vacuo and the crude product was crystallized from methanol-ethyl ether to give 28.1g (81.9% yield) of the hydrochloride salt as colorless needles: mp 190-3°C; ¹H NMR (DMSO-d₆, 400 MHz) δ 2.37 (m, 2H), 2.63 (m, 2H), 3.58 (m, 2H), 5.20 (d, J=10.2 Hz, 2H), 5.28 (dd, J=1.47, 18.6 Hz, 2H), 5.79 (m, 2H), 8.65 (br s, 6H); ¹³C NMR (DMSO-d₆, 100 MHz) δ

-43-

31.59, 51.01, 119.71, 132.33; FAB mass spectrum (GT-HCl) m/z 141 $[M+H]^+$.

D,L-4,5-Diamino-1,7-octadiene dihydrochloride (28.0 g, 131 mmol) was slurried in MeOH (50 ml) and a solution of KOH (14.7 g, 262 mmol) in MeOH (30 ml) was added dropwise under an argon atmosphere with stirring. Ethyl ether (1 l) was added and the mixture was then dried with Na_2SO_4 . The salts were filtered and washed with ethyl ether. The filtrate was concentrated in vacuo to give 17.7 g (95.9% yield) of the diamine as a light yellow liquid: 1H NMR ($CDCl_3$, 300 MHz) δ 1.34 (s, 4H), 2.07 (m, 2H), 2.31 (m, 2H), 2.69 (m, 2H), 5.12 (m, 4H), 5.81 (m, 2H); ^{13}C NMR ($CDCl_3$, 75 MHz) δ 39.68, 54.43, 117.29, 135.98.

References

(1) Neumann, W.L., Rogic, M.M. and Dunn, J.T., Tetrahedron Lett., 32, 5865-8 (1991).

1.B. Synthesis of D,L-N,N'-Bis(chloroacetyl)-4,5-diamino-1,7-octadiene

To a stirred solution of D,L-4,5-diamino-1,7-octadiene prepared as in Example 1A (17.5 g, 124 mmol) in alcohol-free $CHCl_3$ (590 ml) was added H_2O (120 ml) and the resulting mixture was cooled to $0^\circ C$. Solutions of chloroacetyl chloride (43.1 g, 382 mmol) in alcohol-free $CHCl_3$ (235 ml) and K_2CO_3 (49.3 g, 357 mmol) in H_2O (495 ml) were added simultaneously under an argon atmosphere over 1.75 h while maintaining the temperature at $0^\circ C$. The mixture was then allowed to warm to room temperature while stirring an additional 2 h. The layers were separated and the aqueous layer was extracted with $CHCl_3$ (1 l). The combined $CHCl_3$ layers were washed with H_2O (3 x 500 ml), saturated $NaCl$ solution and were dried ($MgSO_4$). The solvent was removed in vacuo to give 35.9

-44-

g (98.4% yield) of the product as a white crystalline solid: mp 120-2°C; ¹H NMR (CDCl₃, 400 MHz) δ 2.37 (m, 2H), 2.44 (m, 2H), 4.03 (m, 6H), 5.16 (m, 4H), 5.76 (m, 2H), 6.90 (d, J=5.4 Hz, 2H); ¹³C NMR (CDCl₃, 100 MHz) δ 36.08, 42.59, 52.33, 119.07, 132.83, 166.68; CI mass spectrum (CH₄) m/z 293 [M+H]⁺.

10 1.C. Synthesis of D,L-5,6-Bis(2-propenyl)-1,10,13-tris-
(p-toluenesulfonyl)-1,4,7,10,13-
pentaazacyclopentadecane-3,8-dione

A solution of 1,4,7-tris(p-toluenesulfonyl)-1,4,7-triazaheptane-1,7-disodium salt (61.0 g, 100 mmol), prepared according to the procedure described in Example 1 of EP Patent Application 0 524 161 A1, in degassed anhydrous DMF (1 l) and a solution of D,L-N,N'-bis(chloroacetyl)-4,5-diamino-1,7-octadiene (29.3 g, 100 mmol) in degassed anhydrous DMF (1 l) were simultaneously added to degassed anhydrous DMF (4 l) under a dry argon atmosphere at room temperature over 4.5 h. The mixture was then stirred for an additional 18 h at room temperature and the solvent was removed in vacuo. The residue was dissolved in CH₂Cl₂ (1l), washed with H₂O (2 x 1 l), saturated NaCl solution (500 ml) and was dried (MgSO₄). The solvent was removed in vacuo to give the crude product as a yellow crystalline solid. The solid was dissolved in CH₂Cl₂ and MeOH (2 l) was added. Crystallization by removal of the CH₂Cl₂ in vacuo gave 47.7 g (60.7% yield) of the product as colorless needles: mp 180-2°C; ¹H NMR (CDCl₃, 300 MHz) δ 1.60 (br s, 2H), 2.26 (m, 2H), 2.45 (s, 9H), 3.19 (m, 4H), 3.45 (m, 4H), 3.70 (dd, J=11.6, 16.1 Hz, 4H), 4.01 (m, 2H), 5.16 (s, 2H), 5.21 (d, J=6.1 Hz, 2H), 5.75 (m, 2H), 6.55 (d, J=7.3 Hz, 2H), 7.33 (m, 6H), 7.70 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 21.58, 36.00, 49.63, 51.50,

-45-

51.71, 54.33, 119.63, 127.51, 127.69, 129.95, 130.09, 132.14, 133.99, 134.40, 143.92, 144.44, 168.37; FAB mass spectrum (NBA-Li) 792.2 [M+Li]⁺.

5 1.D Synthesis of D,L-5,6-Bis(3-hydroxypropyl)-1,10,13-tris-(p-toluenesulfonyl)-1,4,7,10,13-pentaazacyclopentadecane-3,8-dione

To a stirred suspension of D,L-5,6-bis(2-propenyl)-1,10,13-tris-(p-toluenesulfonyl)-1,4,7,10,13-pentaazacyclopentadecane-3,8-dione (20.0 g, 25.5 mmole),
10 prepared as in Example 1C, in anhydrous THF (300 ml) under a dry argon atmosphere was added a solution of borane in THF (63.6 ml - 1.0 M, 63.6 mmole) dropwise over 30 min at 0° C. The solid had dissolved by the end
15 of the addition and stirring was continued at 0°C for another 3 h. Water (10 ml) was then added to destroy excess borohydride and 3 M NaOH (21.2 ml) was then added also at 0°C. Then 30% H₂O₂ (7.23 ml) was added at 0°C and the resulting colorless solution was allowed to warm
20 to room temperature while stirring for another 30 min. Saturated NaCl solution (200 ml) was added to the solution and the product was extracted with ethyl ether (2 X 500 ml). The organic layers were combined and washed with saturated NaCl solution (2 X 100 ml).
25 Product had begun to crystallize from the ether solution. The solvent was removed in vacuo to give a crystalline solid. Crystallization from MeOH - ethyl ether gave 18.2 g (87.0 %) of the product containing secondary alcohol byproduct. Recrystallization of this
30 from CHCl₃ - ethyl ether gave 13.8 g (65.9%) of the product as colorless needles: mp 220 - 2° C; ¹H NMR (CDCl₃, 300 MHz) δ 1.62 (m, 6H), 1.80 (m, 2H), 2.42 (s, 6H), 2.43 (s, 3H), 2.63 (br s, 2H), 3.17 (m, 2H), 3.21 (m, 2H), 3.45 (m, 4H), 3.60 (m, 6H), 3.91 (d, J = 17.1 Hz, 2H), 3.97 (m, 2H), 7.15 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 6H), 7.65 (d, J = 8.3 Hz, 2H), 7.71 (d,

-46-

J = 8.3 Hz, 4H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 21.58, 27.96, 28.80, 49.51, 51.56, 52.68, 54.18, 62.09, 127.45, 127.66, 129.94, 130.09, 133.96, 134.44, 143.86, 144.46, 168.73; FAB mass spectrum (NBA-Li) m/z 828 $[\text{M} + \text{H}]^+$.

5

1.E. Synthesis of D,L-2,3-Bis(3-hydroxypropyl)-
1,4,7,10,13-pentaazacyclopentadecane

To a stirred suspension of D,L-5,6-bis(3-hydroxypropyl)-1,10,13-tris(p-toluenesulfonyl)-
10 1,4,7,10,13-pentaazacyclopentadecane-3,8-dione (5.00 g, 6.08 mmole), prepared as in Example 1D, in anhydrous THF (100 ml) under a dry argon atmosphere was added a solution of 1.0 M LiAlH_4 in THF (76.0 ml, 76.0 mmole) dropwise over 5 minutes. The yellow homogeneous solution
15 was refluxed for 30 h (by which time it had become heterogeneous) and was then cooled to 0°C . The mixture was then quenched by the dropwise addition of saturated Na_2SO_4 (15 ml) while cooling in an ice bath. The solvent was removed in vacuo and any remaining water was removed
20 by azeotroping with toluene (3 X 500 ml) and then hexanes (3 X 500 ml). The solids were then extracted with refluxing, anhydrous, inhibitor-free THF (2 X 500 ml and 2 X 700 ml), filtering the solid each time under an argon atmosphere. The solvent was removed in vacuo
25 from the extracts to give oils which rapidly crystallized. The crude product was purified by crystallization from acetonitrile - ethyl ether to give 500 mg (24.8%) of a colorless crystalline solid: mp $105 - 6^\circ\text{C}$; ^1H NMR (CDCl_3 , 400 MHz) δ 1.59 (m, 4H), 1.70 (m, 4H), 2.73 (m, 25H), 3.51 (m, 2H), 3.66 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 26.85, 27.32, 46.89, 47.97, 48.28, 48.70, 58.17, 62.95; CI mass spectrum (CH_4) 332 $[\text{M} + \text{H}]^+$.

-47-

1.F. Synthesis of [Manganese(II) dichloro trans-2,3-bis(3-hydroxypropyl)-1,4,7,10,13-pentaazacyclopentadecane]

To a stirred solution of anhydrous MnCl_2 (126 mg, 1.00 mmole) in methanol was added D,L-2,3-bis(3-hydroxypropyl)-1,4,7,10,13-pentaazacyclopentadecane prepared as in Example 1E (331 mg, 1.00 mmole) and the solution was refluxed for 2 h and then stirred at room temperature overnight. The solvent was removed *in vacuo* and the white solid was redissolved in a mixture of THF (20 ml) and ethanol (3 ml) and filtered through Celite[®] diatomaceous earth. The filtrate was concentrated to a volume of 3 ml, ethanol (3 ml) was added and the solution was heated to reflux. THF (20 ml) was added to the solution and the crystals which formed were collected to give 820 mg (69%) of the product as a white solid: FAB mass spectrum (NBA - HCl) m/z (relative intensity) 421/423 [$(M - Cl)^+$, 100/33]; Anal. Calcd. For $\text{C}_{16}\text{H}_{37}\text{N}_5\text{MnCl}_2$: C, 42.02; H, 8.15; N, 15.31; Cl, 15.50. Found: C, 42.11; H, 8.14; N, 15.29; Cl, 15.59.

Example 2

Relaxivity measurements of the complex of Example 1 was determined.

Proton relaxation times (T_1) of the sample in 100mM Hepes buffer, pH=7.4, at 40°C were determined from a monoexponential curve fit obtained from inversion-recovery pulse sequences ($180^\circ - \tau - 90^\circ$) with a Bruker PC 120/125/10 VTs NMR process analyzer. The spectrometer was calibrated for each sample to assure accurate duration of 90° and 180° radio frequency pulses and appropriate magnetic field strength to match the 20 MHz system operating frequency. The relaxivity (R_1) was obtained from the slope of a plot of $1/T_1$ versus the concentration of paramagnetic compound.

-48-

The relaxation time (T_2) of each sample in 100 mM Hepes buffer, pH=7.4, was measured at 40°C using a Carr-Purcel-Meiboom-Gill pulse sequence on the same Bruker instrument. The relaxivity (R_2) was obtained from a
5 plot of $1/T_2$ versus the concentration of the paramagnetic compound.


The relaxivity of the complex os Example 1 is as follows: R_1 ($\text{mM}^{-1}\text{sec}^{-1}$) = 2.46 and R_2 ($\text{mM}^{-1}\text{sec}^{-1}$) = 3.19.

-49-

CLAIMS

That which is claimed is:

1. A method of magnetic resonance imaging
5 comprising:
(a) administering to a human or non-human
animal subject a contrast medium comprising a
physiologically compatible complex represented by the
formula:



- wherein at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from
- 20 the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radicals wherein
 - 25 the substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$, $-O-(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$;
 - 30 or at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are independently selected
 - 35 wherein one "R" group of the pair is an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl radical and the

-50-

- other "R" group on the adjacent carbon atom of the macrocycle is a substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radical wherein the
- 5 substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$, $-O(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$;
 - 10 or combinations thereof;
- wherein R_{10} and R_{11} are independently selected from the group consisting of hydrogen and alkyl groups, and a and b are integers independently selected from 1 to 6; and the remaining "R" groups are hydrogen or
- 15 ,optionally, are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylcycloalkyl, cycloalkenylalkyl, alkylcycloalkyl, alkenylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkenyl, heterocyclic,
 - 20 aryl and aralkyl radicals and radicals attached to the α -carbon of α -amino acids; or R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , R_7 or R'_7 and R_8 or R'_8 , and R_9 or R'_9 and R or R' together with the carbon atoms to which they are attached
 - 25 independently form a saturated, partially saturated or unsaturated cyclic having 3 to 20 carbon atoms; or R or R' and R_1 or R'_1 , R_2 or R'_2 and R_3 or R'_3 , R_4 or R'_4 and R_5 or R'_5 , R_6 or R'_6 and R_7 or R'_7 , and R_8 or R'_8 and R_9 or R'_9 together with the carbon atoms to which they are
 - 30 attached independently form a nitrogen containing heterocycle having 2 to 20 carbon atoms provided that when the nitrogen containing heterocycle is an aromatic heterocycle which does not contain a hydrogen attached to the nitrogen, the hydrogen attached to the nitrogen
 - 35 in said formula, which nitrogen is also in the macrocycle and the R groups attached to the same carbon

-51-

- atoms of the macrocycle are absent; and combinations thereof;
- wherein X, Y and Z are ligands independently selected from the group consisting of halide, oxo, aquo, hydroxo,
- 5 alcohol, phenol, dioxygen, peroxo, hydroperoxo, alkylperoxo, arylperoxo, ammonia, alkylamino, arylamino, heterocycloalkyl amino, heterocycloaryl amino, amine oxides, hydrazine, alkyl hydrazine, aryl hydrazine, nitric oxide, cyanide, cyanate, thiocyanate,
- 10 isocyanate, isothiocyanate, alkyl nitrile, aryl nitrile, alkyl isonitrile, aryl isonitrile, nitrate, nitrite, azido, alkyl sulfonic acid, aryl sulfonic acid, alkyl sulfoxide, aryl sulfoxide, alkyl aryl sulfoxide, alkyl sulfenic acid, aryl sulfenic acid, alkyl sulfinic
- 15 acid, aryl sulfinic acid, alkyl thiol⁻carboxylic acid, aryl thiol carboxylic acid, alkyl thiol thiocarboxylic acid, aryl thiol thiocarboxylic acid, alkyl carboxylic acid, aryl carboxylic acid, urea, alkyl urea, aryl urea, alkyl aryl urea, thiourea, alkyl thiourea, aryl
- 20 thiourea, alkyl aryl thiourea, sulfate, sulfite, bisulfate, bisulfite, thiosulfate, thiosulfite, hydrosulfite, alkyl phosphine, aryl phosphine, alkyl phosphine oxide, aryl phosphine oxide, alkyl aryl phosphine oxide, alkyl phosphine sulfide, aryl phosphine
- 25 sulfide, alkyl aryl phosphine sulfide, alkyl phosphonic acid, aryl phosphonic acid, alkyl phosphinic acid, aryl phosphinic acid, alkyl phosphinous acid, aryl phosphinous acid, phosphate, thiophosphate, phosphite, pyrophosphite, triphosphate, hydrogen phosphate,
- 30 dihydrogen phosphate, alkyl guanidino, aryl guanidino, alkyl aryl guanidino, alkyl carbamate, aryl carbamate, alkyl aryl carbamate, alkyl thiocarbamate, aryl thiocarbamate, alkylaryl thiocarbamate, alkyl
- 35 dithiocarbamate, aryl dithiocarbamate, alkylaryl dithiocarbamate, bicarbonate, carbonate, perchlorate, chlorate, chlorite, hypochlorite, perbromate, bromate,

-52-

- bromite, hypobromite, tetrahalomanganate, tetrafluoroborate, hexafluoroantimonate, hypophosphite, iodate, periodate, metaborate, tetraaryl borate, tetraalkyl borate, tartrate, salicylate, succinate, citrate, ascorbate, saccharinate, amino acid, hydroxamic acid, thiosylate, and anions of ion exchange resins, or the corresponding anions thereof, or X, Y and Z are independently attached to one or more of the "R" groups and n is an integer from 0 to 3;
- 10 M is a paramagnetic metal selected from the group consisting of metals having atomic numbers 21-29, 42-44 and 57-71; and a nontoxic, pharmaceutically acceptable carrier, adjuvant or vehicle; and
- (b) generating a magnetic resonance image
- 15 of at least a part of said subject.
2. Method of Claim 1 wherein M is Mn(II) or Gd(III).
3. Method of Claim 2 wherein M is Mn(II).
4. Method of Claim 1 wherein at least one pair
- 20 of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are substituted alkyl, substituted alkenyl, substituted
- 25 alkynyl, substituted cycloalkyl or substituted cycloalkenyl radicals wherein the substituents are independently selected from the group consisting of
- $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-C\equiv NR_{10}R_{11}$, $-O-(-(CH_2)_a-O)_b$, $-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$;
- 30 and the remaining "R" groups are hydrogen or, optionally, are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylcycloalkyl, cycloalkenylalkyl, alkylcycloalkyl, alkenylcycloalkyl,

-53-

alkylcycloalkenyl, alkenylcycloalkenyl, heterocyclic, aryl and aralkyl radicals and radicals attached to the α -carbon of α -amino acids; or R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , R_7 or R'_7 and R_8 or R'_8 , and R_9 or R'_9 and R or R' together with the carbon atoms to which they are attached independently form a saturated, partially saturated or unsaturated cyclic having 3 to 20 carbon atoms; or R or R' and R_1 or R'_1 , R_2 or R'_2 and R_3 or R'_3 , R_4 or R'_4 and R_5 or R'_5 , R_6 or R'_6 and R_7 or R'_7 , and R_8 or R'_8 and R_9 or R'_9 together with the carbon atoms to which they are attached independently form a nitrogen containing heterocycle having 2 to 20 carbon atoms provided that when the nitrogen containing heterocycle is an aromatic heterocycle which does not contain a hydrogen attached to the nitrogen, the hydrogen attached to the nitrogen in said formula, which nitrogen is also in the macrocycle and the R groups attached to the same carbon atoms of the macrocycle are absent; and combinations thereof.

5. Method of Claim 4 wherein R_{10} and R_{11} are hydrogen.

6. Method of Claim 4 wherein said substituents are independently selected from the group selected of $-OR_{10}$ and $-NR_{10}R_{11}$.


7. Method of Claim 6 wherein the "R" groups of the at least one pair of "R" groups on adjacent carbon atoms of the macrocycle are substituted alkyl groups.

8. Method of Claim 4 wherein the "R" groups of the at least one pair of "R" groups on adjacent carbon atoms of the macrocycle are substituted alkyl groups.

9. Method of Claim 8 wherein said substituents on the at least one pair of "R" groups on adjacent carbon atoms of the macrocycle are independently selected from $-OR_{10}$.

10. Method of Claim 9 wherein the complex is:

-54-



11. Method of Claim 1 wherein at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are independently selected wherein one "R" group of the pair is an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl radical and the other "R" group on the adjacent carbon atom of the macrocycle is a substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radical wherein the substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$, $-O-(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$; and the remaining "R" groups are hydrogen or,

-55-

- optionally, are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylcycloalkyl, cycloalkenylalkyl, alkylcycloalkyl, alkenylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkenyl, heterocyclic, aryl and aralkyl radicals and radicals attached to the α -carbon of α -amino acids; or R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , R_7 or R'_7 and R_8 or R'_8 , and R_9 or R'_9 and R or R' together with the carbon atoms to which they are attached independently form a saturated, partially saturated or unsaturated cyclic having 3 to 20 carbon atoms; or R or R' and R_1 or R'_1 , R_2 or R'_2 and R_3 or R'_3 , R_4 or R'_4 and R_5 or R'_5 , R_6 or R'_6 and R_7 or R'_7 , and R_8 or R'_8 and R_9 or R'_9 together with the carbon atoms to which they are attached independently form a nitrogen containing heterocycle having 2 to 20 carbon atoms provided that when the nitrogen containing heterocycle is an aromatic heterocycle which does not contain a hydrogen attached to the nitrogen, the hydrogen attached to the nitrogen in said formula, which nitrogen is also in the macrocycle and the R groups attached to the same carbon atoms of the macrocycle are absent; and combinations thereof.
- 25 12. Method of Claim 11 wherein R_{10} and R_{11} are hydrogen.
13. Method of Claim 11 wherein said substituents are independently selected from the group selected of $-OR_{10}$ and $-NR_{10}R_{11}$.
- 30 14. Method of Claim 13 wherein one "R" group of the at least one pair of "R" groups on adjacent carbon atoms of the macrocycle is an alkyl group and the other "R" group on the adjacent carbon atom of the macrocycle is a substituted alkyl group.
- 35 15. Method of Claim 11 wherein one "R" group of the at least one pair of "R" groups on adjacent carbon


-56-

atoms of the macrocycle is an alkyl group and the other "R" group on the adjacent carbon atom of the macrocycle is a substituted alkyl group.

16. Method of Claim 15 wherein said substituent
5 on the carbon atom of the at least one pair of "R" groups on adjacent carbon atoms of the macrocycle which is a substituted group is $-OR_{10}$.

17. Method of Claim 1 wherein X, Y and Z are
10 independently selected from the group consisting of halide, organic acid, nitrate and bicarbonate anions.

18. A method of diagnostic imaging comprising:
(a) administering to a human or non-human
animal subject a diagnostic agent comprising a
physiologically compatible complex represented by the
15 formula:



wherein at least one pair of "R" groups on adjacent
carbon atoms of the macrocycle selected from the group
consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or
 R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and
30 R_7 or R'_7 and R_8 or R'_8 are substituted alkyl,
substituted alkenyl, substituted alkynyl, substituted
cycloalkyl or substituted cycloalkenyl radicals wherein
the substituents are independently selected from the
group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$,
35 $-CONR_{10}R_{11}$, $-O-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$,

-57-

$-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$;
 or at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are independently selected wherein one "R" group of the pair is an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl radical and the other "R" group on the adjacent carbon atom of the macrocycle is a substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radical wherein the substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$, $-O(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$; or combinations thereof; wherein R_{10} and R_{11} are independently selected from the group consisting of hydrogen and alkyl groups, and a and b are integers independently selected from 1 to 6; and the remaining "R" groups are hydrogen or, optionally, are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylcycloalkyl, cycloalkenylalkyl, alkylcycloalkyl, alkenylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkenyl, heterocyclic, aryl and aralkyl radicals and radicals attached to the α -carbon of α -amino acids; or R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , R_7 or R'_7 and R_8 or R'_8 , and R_9 or R'_9 and R or R' together with the carbon atoms to which they are attached independently form a saturated, partially saturated or unsaturated cyclic having 3 to 20 carbon atoms; or R or R' and R_1 or R'_1 , R_2 or R'_2 and R_3 or R'_3 , R_4 or R'_4 and R_5 or R'_5 , R_6 or R'_6 and R_7 or R'_7 , and R_8 or R'_8 and R_9

-58-

or R', together with the carbon atoms to which they are attached independently form a nitrogen containing heterocycle having 2 to 20 carbon atoms provided that when the nitrogen containing heterocycle is an aromatic heterocycle which does not contain a hydrogen attached to the nitrogen, the hydrogen attached to the nitrogen in said formula, which nitrogen is also in the macrocycle and the R groups attached to the same carbon atoms of the macrocycle are absent; and combinations thereof;

wherein X, Y and Z are ligands independently selected from the group consisting of halide, oxo, aquo, hydroxo, alcohol, phenol, dioxygen, peroxo, hydroperoxo, alkylperoxo, arylperoxo, ammonia, alkylamino, arylamino, heterocycloalkyl amino, heterocycloaryl amino, amine oxides, hydrazine, alkyl hydrazine, aryl hydrazine, nitric oxide, cyanide, cyanate, thiocyanate, isocyanate, isothiocyanate, alkyl nitrile, aryl nitrile, alkyl isonitrile, aryl isonitrile, nitrate, nitrite, azido, alkyl sulfonic acid, aryl sulfonic acid, alkyl sulfoxide, aryl sulfoxide, alkyl aryl sulfoxide, alkyl sulfenic acid, aryl sulfenic acid, alkyl sulfinic acid, aryl sulfinic acid, alkyl thiol carboxylic acid, aryl thiol carboxylic acid, alkyl thiol thiocarboxylic acid, aryl thiol thiocarboxylic acid, alkyl carboxylic acid, aryl carboxylic acid, urea, alkyl urea, aryl urea, alkyl aryl urea, thiourea, alkyl thiourea, aryl thiourea, alkyl aryl thiourea, sulfate, sulfite, bisulfate, bisulfite, thiosulfate, thiosulfite, hydrosulfite, alkyl phosphine, aryl phosphine, alkyl phosphine oxide, aryl phosphine oxide, alkyl aryl phosphine oxide, alkyl phosphine sulfide, aryl phosphine sulfide, alkyl aryl phosphine sulfide, alkyl phosphonic acid, aryl phosphonic acid, alkyl phosphinic acid, aryl phosphinic acid, alkyl phosphinous acid, aryl phosphinous acid, phosphate, thiophosphate, phosphite, pyrophosphite, triphosphate,

-59-

- hydrogen phosphate, dihydrogen phosphate, alkyl
guanidino, aryl guanidino, alkyl aryl guanidino, alkyl
carbamate, aryl carbamate, alkyl aryl carbamate, alkyl
thiocarbamate, aryl thiocarbamate, alkylaryl
5 thiocarbamate, alkyl dithiocarbamate, aryl
dithiocarbamate, alkylaryl dithiocarbamate, bicarbonate,
carbonate, perchlorate, chlorate, chlorite,
hypochlorite, perbromate, bromate, bromite, hypobromite,
tetrahalomanganate, tetrafluoroborate,
10 hexafluoroantimonate, hypophosphite, iodate, periodate,
metaborate, tetraaryl borate, tetra alkyl borate,
tartrate, salicylate, succinate, citrate, ascorbate,
saccharinate, amino acid, hydroxamic acid, thiotosylate,
and anions of ion exchange resins, or the corresponding
15 anions thereof, or X, Y and Z are independently attached
to one or more of the "R" groups and n is an integer
from 0 to 3.
- M is a heavy metal selected from the group consisting of
metals having atomic numbers 20-32, 42-44, 49 and 57-83;
20 and a nontoxic, pharmaceutically acceptable carrier,
adjuvant or vehicle; and


(b) generating an X-ray, ultrasound or
scintigraphic image of at least a part of said subject.

19. Method of Claim 18 wherein M is a radioactive
25 metal isotope selected from the group consisting of ^{99m}Tc
and ^{111}In and said image is a scintigraphic image.

20. A method of radiotherapy practiced on a human
or non-human animal subject comprising administering to
30 said subject a radioactive agent comprising a
physiologically compatible complex represented by the
formula:

-60-

5



- 10 wherein at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and R_7 or R'_7 and R_8 or R'_8 are substituted alkyl,
- 15 substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radicals wherein the substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$, $-O(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$,
- 20 $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and $-OP(O)(OR_{10})(OR_{11})$;
- or at least one pair of "R" groups on adjacent carbon atoms of the macrocycle selected from the group consisting of R_9 or R'_9 and R or R' , R_1 or R'_1 and R_2 or R'_2 , R_3 or R'_3 and R_4 or R'_4 , R_5 or R'_5 and R_6 or R'_6 , and
- 25 R_7 or R'_7 and R_8 or R'_8 are independently selected wherein one "R" group of the pair is an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl radical and the other "R" group on the adjacent carbon atom of the
- 30 macrocycle is a substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl or substituted cycloalkenyl radical wherein the substituents are independently selected from the group consisting of $-OR_{10}$, $-NR_{10}R_{11}$, $-COR_{10}$, $-CO_2R_{10}$, $-CONR_{10}R_{11}$,
- 35 $-O(-(CH_2)_a-O)_b-R_{10}$, $-SR_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2NR_{10}R_{11}$, $-N(OR_{10})(R_{11})$, $-P(O)(OR_{10})(OR_{11})$, $-P(O)(OR_{10})(R_{11})$ and

-61-

-OP(O)(OR₁₀)(OR₁₁);
or combinations thereof;
wherein R₁₀ and R₁₁ are independently selected from the
group consisting of hydrogen and alkyl groups, and a and
5 b are integers independently selected from 1 to 6;
and the remaining "R" groups are hydrogen or
, optionally, are independently selected from the group
consisting of alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkenyl, cycloalkylalkyl, cycloalkylcycloalkyl,
10 cycloalkenylalkyl, alkylcycloalkyl, alkenylcycloalkyl,
alkylcycloalkenyl, alkenylcycloalkenyl, heterocyclic,
aryl and aralkyl radicals and radicals attached to the
α-carbon of α-amino acids; or R₁ or R'₁ and R₂ or R'₂, R₃
or R'₃ and R₄ or R'₄, R₅ or R'₅ and R₆ or R'₆, R₇ or R'₇
15 and R₈ or R'₈, and R₉ or R'₉ and R or R' together with
the carbon atoms to which they are attached
independently form a saturated, partially saturated or
unsaturated cyclic having 3 to 20 carbon atoms; or R or
R' and R₁ or R'₁, R₂ or R'₂ and R₃ or R'₃, R₄ or R'₄ and
20 R₅ or R'₅, R₆ or R'₆ and R₇ or R'₇, and R₈ or R'₈ and R₉
or R'₉ together with the carbon atoms to which they are
attached independently form a nitrogen containing
heterocycle having 2 to 20 carbon atoms provided that
when the nitrogen containing heterocycle is an aromatic
25 heterocycle which does not contain a hydrogen attached
to the nitrogen, the hydrogen attached to the nitrogen
in said formula, which nitrogen is also in the
macrocycle and the R groups attached to the same carbon
atoms of the macrocycle are absent; and combinations
30 thereof;
wherein X, Y and Z are ligands independently selected
from the group consisting of halide, oxo, aquo, hydroxo,
alcohol, phenol, dioxygen, peroxo, hydroperoxo,
alkylperoxo, arylperoxo, ammonia, alkylamino, arylamino,
35 heterocycloalkyl amino, heterocycloaryl amino, amine
oxides, hydrazine, alkyl hydrazine, aryl hydrazine,

-62-

nitric oxide, cyanide, cyanate, thiocyanate,
isocyanate, isothiocyanate, alkyl nitrile, aryl
nitrile, alkyl isonitrile, aryl isonitrile, nitrate,
nitrite, azido, alkyl sulfonic acid, aryl sulfonic acid,
5 alkyl sulfoxide, aryl sulfoxide, alkyl aryl sulfoxide,
alkyl sulfenic acid, aryl sulfenic acid, alkyl sulfinic
acid, aryl sulfinic acid, alkyl thiol carboxylic acid,
aryl thiol carboxylic acid, alkyl thiol thiocarboxylic
acid, aryl thiol thiocarboxylic acid, alkyl carboxylic
10 acid, aryl carboxylic acid, urea, alkyl urea, aryl
urea, alkyl aryl urea, thiourea, alkyl thiourea, aryl
thiourea, alkyl aryl thiourea, sulfate, sulfite,
bisulfate, bisulfite, thiosulfate, thiosulfite,
hydrosulfite, alkyl phosphine, aryl phosphine, alkyl
15 phosphine oxide, aryl phosphine oxide, alkyl aryl
phosphine oxide, alkyl phosphine sulfide, aryl phosphine
sulfide, alkyl aryl phosphine sulfide, alkyl phosphonic
acid, aryl phosphonic acid, alkyl phosphinic acid, aryl
phosphinic acid, alkyl phosphinous acid, aryl
20 phosphinous acid, phosphate, thiophosphate, phosphite,
pyrophosphite, triphosphate, hydrogen phosphate,
dihydrogen phosphate, alkyl guanidino, aryl guanidino,
alkyl aryl guanidino, alkyl carbamate, aryl carbamate,
alkyl aryl carbamate, alkyl thiocarbamate, aryl
25 thiocarbamate, alkylaryl thiocarbamate, alkyl
dithiocarbamate, aryl dithiocarbamate, alkylaryl
dithiocarbamate, bicarbonate, carbonate, perchlorate,
chlorate, chlorite, hypochlorite, perbromate, bromate,
bromite, hypobromite, tetrahalomanganate,
30 tetrafluoroborate, hexafluoroantimonate, hypophosphite,
iodate, periodate, metaborate, tetraaryl borate, tetra
alkyl borate, tartrate, salicylate, succinate, citrate,
ascorbate, saccharinate, amino acid, hydroxamic acid,
thiotosylate, and anions of ion exchange resins, or the
35 corresponding anions thereof, or X, Y and Z are

-63-

independently attached to one or more of the "R" groups
and n is an integer from 0 to 3;
M is a radioactive metal isotope selected from the group
consisting of ^{153}Sm , ^{67}Cu and ^{90}Y ; and a nontoxic,
5 pharmaceutically acceptable carrier, adjuvant or
vehicle.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 96/13045		
A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K49/00 A61K51/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K C07F C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,91 10645 (JULIAN COCKBAIN ET AL.) 25 July 1991 see claims 1,8,10,12,19 ---	1-20
Y	WO,A,82 04252 (BORREGAARD INDUSTRIES LIMITED) 9 December 1982 see claims 1,3,5; figure 3 ---	1-20
Y	EP,A,0 524 161 (MONSANTO COMPANY) 20 January 1993 see abstract; claims 13,14 ---	1-20
A	WO,A,93 14093 (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 22 July 1993 see abstract; claims 1-8 --- <div style="text-align: center;">-/--</div>	
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-size: 1.2em;">28 October 1996</div>		Date of mailing of the international search report <div style="text-align: center; font-size: 1.2em;">14. 11. 96</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer <div style="text-align: center; font-size: 1.2em;">Alvarez Alvarez, C</div>

INTERNATIONAL SEARCH REPORT

In tional Application No
PCT/US 96/13045

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,94 26315 (THE DOW CHEMICAL COMPANY) 24 November 1994 see abstract; claim 1 ---	18,19
A	EP,A,0 588 229 (HOECHST AG.) 23 March 1994 see claims 1,13,14 ---	
A	WO,A,92 21017 (EVAN C. UNGER ET AL.) 26 November 1992 see claims 59-71 ---	
A	WO,A,89 11868 (COULTER ELECTRONICS, INC.) 14 December 1989 see claims 46,52,53,56 ---	
A	WO,A,93 12097 (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 24 June 1993 see claims 46-50,27; figure 7 ---	
A	EP,A,0 287 465 (GUERBET S.A.) 19 October 1988 see page 1, line 1 - page 2, line 55 see page 8, line 56 - line 63 see page 9, line 17 - line 21 ---	1-20
P,X	WO,A,95 28968 (MONSANTO COMPANY ET AL.) 2 November 1995 see the whole document -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 13045

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: ALL
because they relate to subject matter not required to be searched by this Authority, namely:
All the claims are excluded from patentability, Art. 52(4) "diagnostic method practised on human or animal body"
Our search has been aimed to the use of the claimed products for diagnosis.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In uonal Application No

PCT/US 96/13045

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9110645	25-07-91	AU-A- 7060291 EP-A- 0527131	05-08-91 17-02-93
WO-A-8204252	09-12-82	EP-A- 0080478	08-06-83
EP-A-524161	20-01-93	AU-B- 661023 AU-A- 2338392 CA-A- 2072897 CA-A- 2072934 EP-A- 0598753 JP-T- 6509566 NZ-A- 272364 WO-A- 9302090 ZA-A- 9205139	13-07-95 23-02-93 20-01-93 20-01-93 01-06-94 27-10-94 27-02-96 04-02-93 26-04-93
WO-A-9314093	22-07-93	US-A- 5252720 AU-A- 3436793 CA-A- 2127530 EP-A- 0623134 FI-A- 943445 JP-T- 7503009 NO-A- 942719 NZ-A- 246795 US-A- 5432171 US-A- 5475104 US-A- 5439570 US-A- 5451576 US-A- 5457183 US-A- 5559207 US-A- 5504205 US-A- 5565552	12-10-93 03-08-93 22-07-93 09-11-94 20-07-94 30-03-95 19-09-94 27-02-96 11-07-95 12-12-95 08-08-95 19-09-95 10-10-95 24-09-96 02-04-96 15-10-96
WO-A-9426315	24-11-94	AU-A- 4237493	12-12-94
EP-A-588229	23-03-94	JP-A- 6228114	16-08-94
WO-A-9221017	26-11-92	AU-B- 660033 AU-A- 1998792 AU-A- 3053695 CA-A- 2102605	08-06-95 30-12-92 09-11-95 24-11-92

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/13045

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9221017		EP-A- 0594640 JP-T- 6507904 US-A- 5466438 US-A- 5312617	04-05-94 08-09-94 14-11-95 17-05-94
WO-A-8911868	14-12-89	AU-A- 3831389 EP-A- 0369000 JP-T- 2504640 US-A- 5373093	05-01-90 23-05-90 27-12-90 13-12-94
WO-A-9312097	24-06-93	US-A- 5316757 AU-A- 2912492 CA-A- 2125773 CN-A- 1073680 EP-A- 0618910 JP-T- 7502994 NZ-A- 244795 NZ-A- 264440 PT-A- 101123 US-A- 5428155 ZA-A- 9208338	31-05-94 19-07-93 24-06-93 30-06-93 12-10-94 30-03-95 26-07-95 26-07-95 28-02-94 27-06-95 04-05-93
EP-A-287465	19-10-88	FR-A- 2614020 AU-B- 606146 AU-A- 1461188 CN-B- 1022411 DE-A- 3877799 DK-B- 170946 ES-T- 2053779 FI-B- 93830 IE-B- 62582 JP-A- 1211573 NO-B- 176839 US-A- 5417960 US-A- 5049667 ZA-A- 8802552	21-10-88 31-01-91 20-10-88 13-10-93 11-03-93 25-03-96 01-08-94 28-02-95 08-02-95 24-08-89 27-02-95 23-05-95 17-09-91 27-09-88
WO-A-9528968	02-11-95	AU-A- 2128895	16-11-95